Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Srikumar M. Raja, Robert J. Clubb, Cesar Ortega-Cava, Stetson H. Williams, Tameka A. Bailey, Lei Duan, Xiangshan Zhao, Alagarasamy L. Reddi, Abijah M. Nyong, Amarnath Natarajan, Vimla Band & Hamid Band. (2011) Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biology & Therapy 11:2, pages 263-276.
Read now
Read now
Articles from other publishers (57)
Kejun Yin & Ronghu Wu. (2023) Investigation of Cellular Response to the HSP90 Inhibition in Human Cells Through Thermal Proteome Profiling. Molecular & Cellular Proteomics 22:6, pages 100560.
Crossref
Crossref
Nora Astrain-Redin, Carmen Sanmartin, Arun K. Sharma & Daniel Plano. (2023) From Natural Sources to Synthetic Derivatives: The Allyl Motif as a Powerful Tool for Fragment-Based Design in Cancer Treatment. Journal of Medicinal Chemistry 66:6, pages 3703-3731.
Crossref
Crossref
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza & Giuseppe Curigliano. (2023) Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers 15:4, pages 1130.
Crossref
Crossref
Kyler W. Pugh, Marim Alnaed, Christopher M. Brackett & Brian S. J. Blagg. (2022) The biology and inhibition of glucose‐regulated protein 94/gp96. Medicinal Research Reviews 42:6, pages 2007-2024.
Crossref
Crossref
Pei Wang, Biaoqi Chen, Yunyan Zhan, Lianguo Wang, Jun Luo, Jia Xu, Lilin Zhan, Zhihua Li, Yuangang Liu & Junchao Wei. (2022) Enhancing the Efficiency of Mild-Temperature Photothermal Therapy for Cancer Assisting with Various Strategies. Pharmaceutics 14:11, pages 2279.
Crossref
Crossref
Megha Yadav, Ankit Kumar Singh, Adarsh Kumar, Suresh Thareja & Pradeep Kumar. (2022) An Insight to Heat Shock Protein 90: A Remedy for Multiple Problems. Current Pharmaceutical Design 28:32, pages 2664-2676.
Crossref
Crossref
Sumera Zaib, B. S. Areeba, B. S. Nehal Rana, Javed Iqbal Wattoo, Hashem O. Alsaab, Rami M. Alzhrani, Nasser S. Awwad, Hala A. Ibrahium & Imtiaz Khan. (2022) Nanomedicines Targeting Heat Shock Protein 90 Gene Expression in the Therapy of Breast Cancer. ChemistrySelect 7:14.
Crossref
Crossref
Yuqing Tang, Dongju Zhao, Fan Yang, Gaoju Pang, Zuhao Sun, Jin Chang & Yan Dou. (2022) Hsp90 co-chaperone degradation combined with antioxidation nanostrategy to rescue tauopathy-induced Alzheimer’s disease. Chemical Engineering Journal 432, pages 134352.
Crossref
Crossref
Elena Díaz-Rodríguez, Lucía Gandullo-Sánchez, Alberto Ocaña & Atanasio Pandiella. (2021) Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers 14:1, pages 154.
Crossref
Crossref
Haitao Luan, Tameka A. Bailey, Robert J. Clubb, Bhopal C. Mohapatra, Aaqib M. Bhat, Sukanya Chakraborty, Namista Islam, Insha Mushtaq, Matthew D. Storck, Srikumar M. Raja, Vimla Band & Hamid Band. (2021) CHIP/STUB1 Ubiquitin Ligase Functions as a Negative Regulator of ErbB2 by Promoting Its Early Post-Biosynthesis Degradation. Cancers 13:16, pages 3936.
Crossref
Crossref
Min Ye, Wei Huang, Rui Liu, Yingli Kong, Yang Liu, Xiaole Chen & Jianhua Xu. (2021) Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells. Frontiers in Pharmacology 12.
Crossref
Crossref
Yuesheng Zhang. (2021) The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. Pharmacology & Therapeutics 218, pages 107677.
Crossref
Crossref
Shufang Liu & Dhaval K. Shah. 2021. Quantitative Analysis of Cellular Drug Transport, Disposition, and Delivery. Quantitative Analysis of Cellular Drug Transport, Disposition, and Delivery
331
355
.
Pengrong Yan, Hardik J. Patel, Sahil Sharma, Adriana Corben, Tai Wang, Palak Panchal, Chenghua Yang, Weilin Sun, Thais L. Araujo, Anna Rodina, Suhasini Joshi, Kenneth Robzyk, Srinivasa Gandu, Julie R. White, Elisa de Stanchina, Shanu Modi, Yelena Y. Janjigian, Elizabeth G. Hill, Bei Liu, Hediye Erdjument-Bromage, Thomas A. Neubert, Nanette L.S. Que, Zihai Li, Daniel T. Gewirth, Tony Taldone & Gabriela Chiosis. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. Cell Reports 31:13, pages 107840.
Crossref
Crossref
Sara García-Alonso, Alberto Ocaña & Atanasio Pandiella. (2020) Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. Trends in Cancer 6:2, pages 130-146.
Crossref
Crossref
Sona Talaei, Hassan Mellatyar, Asadollah Asadi, Abolfazl Akbarzadeh, Roghayeh Sheervalilou & Nosratollah Zarghami. (2019)
Spotlight on 17‐
AAG
as an Hsp90 inhibitor for molecular targeted cancer treatment
. Chemical Biology & Drug Design 93:5, pages 760-786.
Crossref
Crossref
Sona Talaei, Hassan Mellatyar, Younes Pilehvar-Soltanahmadi, Asadollah Asadi, Abolfazl Akbarzadeh & Nosratollah Zarghami. (2019) 17-Allylamino-17-demethoxygeldanamycin loaded PCL/PEG nanofibrous scaffold for effective growth inhibition of T47D breast cancer cells. Journal of Drug Delivery Science and Technology 49, pages 162-168.
Crossref
Crossref
Kang-Seo Park, Yong Sang Hong, Junyoung Choi, Shinkyo Yoon, Jihoon Kang, Deokhoon Kim, Kang-Pa Lee, Hyeon-Su Im, Chang Hoon Lee, Seyoung Seo, Sang-We Kim, Dae Ho Lee & Sook Ryun Park. (2018) HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. BMB Reports 51:12, pages 660-665.
Crossref
Crossref
Alexandra Canonici, Zulfiqar Qadir, Neil T. Conlon, Denis M. Collins, Neil A. O’Brien, Naomi Walsh, Alex J. Eustace, Norma O’Donovan & John Crown. (2018) The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. Investigational New Drugs 36:4, pages 581-589.
Crossref
Crossref
Harry Lee, Nipun Saini, Erin W. Howard, Amanda B. Parris, Zhikun Ma, Qingxia Zhao, Ming Zhao, Bolin Liu, Susan M. Edgerton, Ann D. Thor & Xiaohe Yang. (2018) Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. Scientific Reports 8:1.
Crossref
Crossref
Meng Xiao, Ming Yan, Jianjun Zhang, Qin Xu & Wantao Chen. (2017) Carboxy-terminus Hsc70 interacting protein exerts a tumor inhibition function in head and neck cancer. Oncology Reports.
Crossref
Crossref
Hang Zhang, Yuxi Wang, Yangping Wu, Xiaohua Jiang, Yiran Tao, Yuqin Yao, Yujia Peng, Xiangzheng Chen, Yuyin Fu, Lin Yu, Ruixue Wang, Qinhuai Lai, Weirong Lai, Wenting Li, Yuhuan Kang, Shuli Yi, Ying Lu, Lantu Gou, Min Wu & Jinliang Yang. (2017) Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer. Signal Transduction and Targeted Therapy 2:1.
Crossref
Crossref
Patrizio Castagnola, Grazia Bellese, Filippo Birocchi, Maria Cristina Gagliani, Carlo Tacchetti & Katia Cortese. (2016) Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells. Oncotarget 7:51, pages 85411-85429.
Crossref
Crossref
Lovisa Göstring, Sture Lindegren & Lars Gedda. (2016) 17AAG-induced internalisation of HER2-specific Affibody molecules. Oncology Letters 12:4, pages 2574-2580.
Crossref
Crossref
Srikumar M. Raja, Swapnil S. Desale, Bhopal Mohapatra, Haitao Luan, Kruti Soni, Jinjin Zhang, Matthew A. Storck, Dan Feng, Timothy A. Bielecki, Vimla Band, Samuel M. Cohen, Tatiana K. Bronich & Hamid Band. (2016) Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. Oncotarget 7:9, pages 10522-10535.
Crossref
Crossref
Brigitte Bisaro, Marianna Sciortino, Shana Colombo, Maria Pilar Camacho Leal, Andrea Costamagna, Isabella Castellano, Filippo Montemurro, Valentina Rossi, Giorgio Valabrega, Emilia Turco, Paola Defilippi & Sara Cabodi. (2015) p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. Oncotarget 7:4, pages 4442-4453.
Crossref
Crossref
Swapnil S. Desale, Srikumar M. Raja, Jong Oh Kim, Bhopal Mohapatra, Kruti S. Soni, Haitao Luan, Stetson H. Williams, Timothy A. Bielecki, Dan Feng, Matthew Storck, Vimla Band, Samuel M. Cohen, Hamid Band & Tatiana K. Bronich. (2015) Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models. Journal of Controlled Release 208, pages 59-66.
Crossref
Crossref
Zuzana Sol�rov�, J�n Mojžiš & Peter Sol�r. (2014) Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (Review). International Journal of Oncology.
Crossref
Crossref
Tameka A. Bailey, Haitao Luan, Eric Tom, Timothy Alan Bielecki, Bhopal Mohapatra, Gulzar Ahmad, Manju George, David L. Kelly, Amarnath Natarajan, Srikumar M. Raja, Vimla Band & Hamid Band. (2014) A Kinase Inhibitor Screen Reveals Protein Kinase C-dependent Endocytic Recycling of ErbB2 in Breast Cancer Cells. Journal of Biological Chemistry 289:44, pages 30443-30458.
Crossref
Crossref
Edward L Nelson. (2014) HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium. Clinical Investigation 4:7, pages 649-671.
Crossref
Crossref
Thulani H. Senanayake, Yaman Lu, Anna Bohling, Srikumar Raja, Hamid Band & Serguei V. Vinogradov. (2014) Encapsulation of Poorly Soluble Drugs in Polymer-Drug Conjugates: Effect of Dual-Drug Nanoformulations on Cancer Therapy. Pharmaceutical Research 31:6, pages 1605-1615.
Crossref
Crossref
Shuo Qie, Clarissa Chu, Weihua Li, Chenguang Wang & Nianli Sang. (2014) ErbB2 Activation Upregulates Glutaminase 1 Expression Which Promotes Breast Cancer Cell Proliferation. Journal of Cellular Biochemistry 115:3, pages 498-509.
Crossref
Crossref
Chao Sun, Hai-Long Li, Mei-Lin Shi, Qing-Hua Liu, Jin Bai & Jun-Nian Zheng. (2013) Diverse roles of C-terminal Hsp70-interacting protein (CHIP) in tumorigenesis. Journal of Cancer Research and Clinical Oncology 140:2, pages 189-197.
Crossref
Crossref
Flora Zagouri, Theodoros N. Sergentanis, Dimosthenis Chrysikos, Christos A. Papadimitriou, Meletios-Athanassios Dimopoulos & Theodora Psaltopoulou. (2013) Hsp90 inhibitors in breast cancer: A systematic review. The Breast 22:5, pages 569-578.
Crossref
Crossref
David S. Hong, Udai Banerji, Bahareh Tavana, Goldy C. George, Joann Aaron & Razelle Kurzrock. (2013) Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. Cancer Treatment Reviews 39:4, pages 375-387.
Crossref
Crossref
Katia Cortese, Mark T. Howes, Richard Lundmark, Erica Tagliatti, Paola Bagnato, Annalisa Petrelli, Maria Bono, Harvey T. McMahon, Robert G. Parton & Carlo Tacchetti. (2013) The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments. Molecular Biology of the Cell 24:2, pages 129-144.
Crossref
Crossref
Ningyan Zhang, Melvin E. Klegerman, Hui Deng, Yun Shi, Eva Golunski & Zhiqiang An. (2013) Trastuzumab-Doxorubicin Conjugate Provides Enhanced Anti-Cancer Potency and Reduced Cardiotoxicity. Journal of Cancer Therapy 04:01, pages 308-322.
Crossref
Crossref
Dimitrios Zardavas, Lina Pugliano, Felipe Ades, Ivana Bozovic-Spasojevic, Marta Capelan & Evandro de Azambuja. (2012) Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond. Breast Cancer Management 1:3, pages 217-233.
Crossref
Crossref
Juliana Bentes Hughes, Marianne Skeie Rødland, Max Hasmann, Inger Helene Madshus & Espen Stang. (2012) Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab. Pharmaceuticals 5:7, pages 674-689.
Crossref
Crossref
Aleksandra Glogowska, Jörg Stetefeld, Ekkehard Weber, Saeid Ghavami, Cuong Hoang-Vu & Thomas Klonisch. (2012) Epidermal Growth Factor Cytoplasmic Domain Affects ErbB Protein Degradation by the Lysosomal and Ubiquitin-Proteasome Pathway in Human Cancer Cells. Neoplasia 14:5, pages 396-IN5.
Crossref
Crossref
Qing Cheng, Jeffrey T Chang, Joseph Geradts, Leonard M Neckers, Timothy Haystead, Neil L Spector & H Kim Lyerly. (2012) Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Research 14:2.
Crossref
Crossref
Naomi Ono, Toshikazu Yamazaki, Yoshito Nakanishi, Toshihiko Fujii, Kiyoaki Sakata, Yukako Tachibana, Atsushi Suda, Kihito Hada, Takaaki Miura, Shigeo Sato, Ryoichi Saitoh, Kohnosuke Nakano, Takuo Tsukuda, Toshiyuki Mio, Nobuya Ishii, Osamu Kondoh & Yuko Aoki. (2012) Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Science 103:2, pages 342-349.
Crossref
Crossref
Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi & Luca Gianni. (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology 9:1, pages 16-32.
Crossref
Crossref
Moïse Namer, Michel Héry, Marc Spielmann, Joseph Gligorov & Frédérique Penault-LlorcaS. Guiu, B. Coudert & P. Fumoleau. 2012. Cancer du sein. Cancer du sein
499
528
.
Peter Solár, Mária Chytilová, Zuzana Solárová, Ján Mojžiš, Peter Ferenc & Peter Fedoročko. (2011) Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins. Pharmaceuticals 4:11, pages 1488-1502.
Crossref
Crossref
Yan-yan Yan, Li-sheng Zheng, Xu Zhang, Li-kun Chen, Satyakam Singh, Fang Wang, Jian-ye Zhang, Yong-ju Liang, Chun-ling Dai, Lian-quan Gu, Mu-sheng Zeng, Tanaji T. Talele, Zhe-sheng Chen & Li-wu Fu. (2011)
Blockade of Her2/
neu
Binding to Hsp90 by Emodin Azide Methyl Anthraquinone Derivative Induces Proteasomal Degradation of Her2/
neu
. Molecular Pharmaceutics 8:5, pages 1687-1697.
Crossref
Crossref
Maurizio Scaltriti, Violeta Serra, Emmanuel Normant, Marta Guzman, Olga Rodriguez, Alice R. Lim, Kelly L. Slocum, Kip A. West, Varenka Rodriguez, Ludmila Prudkin, José Jimenez, Claudia Aura & José Baselga. (2011) Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Molecular Cancer Therapeutics 10:5, pages 817-824.
Crossref
Crossref
Meletios-Athanassios Dimopoulos, Constantine S. Mitsiades, Kenneth C. Anderson & Paul G. Richardson. (2011) Tanespimycin as Antitumor Therapy. Clinical Lymphoma Myeloma and Leukemia 11:1, pages 17-22.
Crossref
Crossref
Luisa Paris, Serena Cecchetti, Francesca Spadaro, Laura Abalsamo, Luana Lugini, Maria Elena Pisanu, Egidio Iorio, Pier Giorgio Natali, Carlo Ramoni & Franca Podo. (2010) Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Research 12:3.
Crossref
Crossref
Corina Marx, Jason M. Held, Bradford W. Gibson & Christopher C. Benz. (2010) ErbB2 Trafficking and Degradation Associated with K48 and K63 Polyubiquitination. Cancer Research 70:9, pages 3709-3717.
Crossref
Crossref
Windy Dean-Colomb & Francisco J. Esteva. (2010) Treatment of Her2-Positive Breast Cancer: What’s on the Horizon. Current Breast Cancer Reports 2:1, pages 42-52.
Crossref
Crossref
Marco A. Biamonte, Ryan Van de Water, Joseph W. Arndt, Robert H. Scannevin, Daniel Perret & Wen-Cherng Lee. (2009) Heat Shock Protein 90: Inhibitors in Clinical Trials. Journal of Medicinal Chemistry 53:1, pages 3-17.
Crossref
Crossref
Byung Min Chung, Srikumar M Raja, Robert J Clubb, Chun Tu, Manju George, Vimla Band & Hamid Band. (2009) Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src@. BMC Cell Biology 10:1.
Crossref
Crossref
Matteo LandriscinaFrancesca MaddalenaGabriella LaudieroFranca Esposito. (2009) Adaptation to Oxidative Stress, Chemoresistance, and Cell Survival. Antioxidants & Redox Signaling 11:11, pages 2701-2716.
Crossref
Crossref
Beata Zahorowska, Philip J. Crowe & Jia-Lin Yang. (2009) Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. Journal of Cancer Research and Clinical Oncology 135:9, pages 1137-1148.
Crossref
Crossref
Gang Niu, Zibo Li, Qizhen Cao & Xiaoyuan Chen. (2009) Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumab. European Journal of Nuclear Medicine and Molecular Imaging 36:9, pages 1510-1519.
Crossref
Crossref
Jasmine V. Abella & Morag Park. (2009) Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. American Journal of Physiology-Endocrinology and Metabolism 296:5, pages E973-E984.
Crossref
Crossref